Skip to content
CU Logo

University of Colorado Anschutz Medical Campus

Anschutz

  • Webmail
  • UCD Access
  • Canvas
  • Quick Links
 

Locations

  • CU Denver
  • CU Anschutz Medical Campus
  • CU South Denver
  • CU Online

Tools

  • Webmail
  • UCDAccess
  • Canvas
  • Directory
  • A-Z
  • Faculty & Staff
  • University Policies
  • Auraria Library
  • Strauss Health Sciences Library

Schools and Colleges

CU Denver

  • College of Architecture and Planning
  • College of Arts & Media
  • Business School
  • School of Education & Human Development
  • College of Engineering, Design and Computing
  • Graduate School
  • College of Liberal Arts and Sciences
  • School of Public Affairs

CU Anschutz Medical Campus

  • School of Dental Medicine
  • Graduate School
  • School of Medicine
  • College of Nursing
  • Skaggs School of Pharmacy and Pharmaceutical Sciences
  • Colorado School of Public Health

Barbara Davis Center for Childhood Diabetes

School of Medicine

  • Patient Care
    • Pediatric Clinic
    • Adult Clinic
    • Eye Clinic
  • Patient and Provider Resources
    • Clinical Care Resources
    • Publications
    • Patient Programs
  • Research
    • Basic and Translational Research Division
    • Clinical Research
    • Clinical Epidemiology
  • News & Events
    • BDC in the News
    • Conferences and Training
    • Events and Announcements
    • 3rd Childhood Diabetes Prevention Symposium
  • Core Facilities
    • Autoantibody/HLA Core Facility
    • Cytometry Core Facility
    • Islet Core Facility
    • Molecular Biology Core Facility
  • Donate
  • About
    • Leadership
    • Faculty
    • Contact Us
    • Children's Diabetes Foundation

Free CU Anschutz COVID-19 Antibody Tests to Fuel Diabetes Study

Barbara Davis Center wants to know: Does SARS-CoV-2 trigger diabetes?

Full Story

Artificial Pancreas System Better Controls Blood Glucose Levels Than Current Technology

Full Story

One-Hour OGTT As Accurate As Two Hr OGTT For Diabetes Detection, Finds Study

Full Story

Barbara Davis Center in the News


“Use your blood glucose meter to help improve your health”

Our very own peds nurses Ashlee Ernst and Betsy Otten wrote this piece entitled “Use your blood glucose meter to help improve your health” published on Diatribe.org

https://diatribe.org/use-your-blood-glucose-meter-help-you-improve-your-health

T1GER study shows benefit of golimumab in newly diagnosed T1D: Box Title

Dr. Andrea Steck and her team participated in a phase II, multicenter, randomized, placebo-controlled trial examining the effects of golimumab, a TNF-α inhibitor, in pediatric type 1 diabetes (T1D). Children and young adults with newly diagnosed T1D had better endogenous insulin production and less exogenous insulin use after taking golimumab for 52 weeks, compared with those who took placebo. Mean 4-hour C-peptide area under the curve, as well as the number of those who had a partial-remission response, were higher in those who took golimumab, compared with those who took placebo.

https://www.nejm.org/doi/full/10.1056/NEJMoa2006136

FEATURED: Studies Find Better Glucose Control When Using Continuous Glucose Monitoring Devices

Continuous Glucose Monitors (CGM) are small devices that continually measure glucose levels under the skin, and transmit this information to a wireless device such as a receiver or cell phone. Two large multi-center studies recently published in the Journal of the American Medical Association (JAMA) tested if these devices improved glycemic control or reduced incidence of life-threatening low glucose levels in two very unique populations: adolescents and older adults living with type 1 diabetes. The CITY (CGM Intervention in Teens and Young Adults with type 1 diabetes) trial was a six month randomized controlled trial that showed that CGM helps adolescents and young adults manage their type 1 diabetes more effectively, compared with daily use of blood glucose finger-stick testing. The CGM users saw significant reductions in their hemoglobin A1C levels and less time spent with severe high and low blood glucose levels. Barbara Davis Center clinical and research staffs, including investigators Laurel Messer, PhD, Viral Shah, MD and Paul Wadwa, MD, were involved in the conduct of both landmark clinical trials.

Links to the two press releases are found here:

Release 1 - "Study Finds Better Glucose Control for Young People Using Continuous Monitoring Devices"

Release 2 - "Continuing Glucose Monitoring Reduces Hypoglycemia in Older Adults With Type 1 Diabetes"

Links to the two articles are found here:

https://jamanetwork.com/journals/jama/article-abstract/2767160

https://jamanetwork.com/journals/jama/article-abstract/2767159

9NEWS Q&A: Can the coronavirus trigger type 1 diabetes in kids?

The Barbara Davis Center for Diabetes saw a 40% increase in Type 1 Diabetes during the pandemic.

Diabetes treatment centers saw a surge in type 1 diabetes patients that may correlate with the coronavirus pandemic.That's according to Dr. Brigitte Frohnert, associate professor at the Barbara Davis Center for Childhood Diabetes at University of Colorado-Anshutz. 

9NEWS sat down with Frohnert to discuss causes for type 1 diabetes, an autoimmune disorder, and how the coronavirus may play a role in triggering it.

Link to Full Interview  Author: Katie Eastman

 

Artificial pancreas effectively controls type 1 diabetes in children age 6 and up

The artificial pancreas is an “all-in-one” diabetes management system that tracks blood glucose levels using a continuous glucose monitor and automatically delivers insulin when needed

A clinical trial at the Barbara Davis Center for Childhood Diabetes at the University of Colorado Anschutz Medical Center and three other pediatric diabetes centers in the United States has found that a new artificial pancreas system — which automatically monitors and regulates blood glucose levels — is safe and effective at managing blood glucose levels in children as young as age six with type 1 diabetes. The trial was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health. Results from the trial were published August 26 in the New England Journal of Medicine.

FEATURED: An Ultradian Notch in Beta-Cell Development, Utpal B. Pajvani, M.D., Ph.D., and Lori Sussel, Ph.D.

Published in the New England Journal of Medicine 383(1):80-82 · July 2020

A study of genetically manipulated mouse models has shown that ultradian cycles of expression of a particular protein influence specification of cell type in the pancreas, a finding that has implications for understanding beta-cell identity and function.

Link to full article in the New England Journal of Medicine

Dr. Andrea Gerard Gonzalez discusses how for diabetes patients, new health threats and cost concerns surface during coronavirus.

Full Story >>

Uchenna 2

NFL player, Uchenna Nwosu visits the Barbara Davis Center and plays football with kids

Full Story >>

 

Dr. Aaron Michels' Research using Methyldopa for Prevention of T1D.

Full Story>>

 ultra-sound-diabetes-4

Dr. Richard Benninger and Richard Ramirez use ultrasound technology to track T1D

Full Story>>

SatishGarg-web-optimized_300

Dr. Satish Garg talks about first-ever oral drug for T1D

Full Story>>

TEDDY_IMAGE

Participating in T1D Trials, The Value of Knowing 

Full Story>>

  
ASK

"Just ASK to Know:" One family's journey before and after screening for T1D

Full Story>>

 

 

Events

Conferences and Training

CU School of Medicine Media Relations

Mark Couch - Director of Communications, Chief of Staff

Phone: 303.724-5377

  • Contact Us
  • Website Feedback
  • CU System
  • Privacy Policy
  • Terms of Use
  • Accreditation
  • Employment
  • Give Now
 

© 2020 The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.

CMS Login

Webmail

UCD Access

Canvas